A stilbenol that is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4' by hydroxy groups.
Chemical ID:
MESH:C059514
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Resveratrol inhibits the reaction [AGT protein modified form results in increased expression of RPS6KB1 protein modified form]; Resveratrol inhibits the reaction [AGT protein modified form results in increased phosphorylation of RPS6KB1 protein]; Resveratrol inhibits the reaction [IGF1 protein results in increased expression of RPS6KB1 protein modified form]; Resveratrol inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Resveratrol results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Resveratrol results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Resveratrol results in decreased activity of RPS6KB1 protein] which results in decreased phosphorylation of RPS6 protein; [Resveratrol results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Resveratrol results in increased abundance of Calcium] which results in decreased expression of RPS6KB1 protein modified form; dorsomorphin inhibits the reaction [[Resveratrol results in increased abundance of Calcium] which results in decreased expression of RPS6KB1 protein modified form]; Resveratrol inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]; TSC2 mutant form inhibits the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]
[[resveratrol results in increased activity of SIRT1 protein] which results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; resveratrol inhibits the reaction [AGT protein modified form results in increased expression of RPS6KB1 protein modified form]; resveratrol inhibits the reaction [TNF protein results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [resveratrol results in decreased phosphorylation of RPS6KB1 protein]
